CB 001 - Ceronco Biosciences
Alternative Names: CB-001 - Ceronco Biosciences; Doxorubicin liposomal - Ceronco Biosciences; GC enriched liposomal doxorubicin - Ceronco Biosciences; Glucosylceramide enriched doxorubicin - Ceronco BiosciencesLatest Information Update: 28 Nov 2020
At a glance
- Originator Ceronco Biosciences
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer; Soft tissue sarcoma
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in Netherlands
- 28 Nov 2020 No recent reports of development identified for preclinical development in Soft tissue sarcoma in Netherlands
- 26 Oct 2016 Preclinical trials in Ovarian cancer in Netherlands (unspecified route)